Hyogo Prefectural Nishinomiya Hospital, Nishinomiya, Japan
Hiroyuki Narahara , Kayo Yasuda , Kaori Morita , Hitoshi Matsumoto , Yuichi Yasunaga , Yoshiaki Inui , Sumio Kawata , Katsuhito Takahashi , Satoshi Teraoka
Background: We established the Japan Sarcoma Association and hold the Japan-United States International Workshop on the Sarcoma Research and Therapy in December 2014. Aim: We conducted a retrospective analysis on pazopanib for STS in order to examine the relationships of PFS with denosumab, also from the viewpoint of the first-line setting for metastatic diseases. Methods: In this study, the patients with metastatic STS treated with pazopanib from November 2012 till January 2015, consecutively, were retrospectively analyzed. Among first 4 months, the starting dose was fixed at 800mg, but later changed to 400mg because of severe adverse events. Results: Eighty seven patients (43 leiomyosarcomas, 8 liposarcomas, 36 other subtypes) were identified. Median age was 56 years old (range 17-84), 69 females and 18 males, 50 pts were treated in the first-line setting and 37 pts were in the second or later-line setting, and 26 pts with multiple bone metastases were all treated with denosumab. Remarkable severe toxicities (G 3/4) were observeded as pheumothorax, hyperbilirubinemia, bladder perforation and perianal abscess, but the rates were infrequent ( < 2.2%). All hypertension was manageable by anti-hypertensive medication and cardio-echogram showed no decrease of EF and it was definitly < 10%. But seum BNP increaseded in some pts. No pts showed symptomatic heart failure in the observation period (median: one year). All the pts, included till July 2014, were evaluable by RECIST 1.1, and 37 pts were evaluated as PR/SD and 31 pts showed PD/NE. Median OS reached 16.9 months (95%CI: 9.7-ND) and median PFS was 2.6 months (95%CI: 2.2-3.7). From the viewpoint of PFS with response, PFS in PR and that in SD were similar. PFS showed no differences between 800mg vs 400mg, leiomyosarcoma vs liposarcoma vs others, PS 0/1 vs 2/3 and 1st line vs later line. But PFS in PR/SD was longer (4.9 months, 95%CI: 2.8-7.1) than that in PD/NE (1.7 months, 95%CI: 1.1-2.3, p < 0.0001). PFS with denosumab was not inferior to that without denosumab. Conclusions: Pazopanib including first-line setting for metastatic STS is effective and comparable with EORTC trials. The combination chemotherapy of pazopanib with denosumab is promising and further investigations are warranted.
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Abstract Disclosures
2022 ASCO Annual Meeting
First Author: Minggui Pan
2022 ASCO Annual Meeting
First Author: Tao Li
2023 ASCO Annual Meeting
First Author: Lee D. Cranmer
2022 ASCO Annual Meeting
First Author: Ahmet Bilici